Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 404 for:    LEVONORGESTREL

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users (WESAIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02362373
Recruitment Status : Completed
First Posted : February 12, 2015
Results First Posted : January 18, 2016
Last Update Posted : January 18, 2016
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Anne Davis, Columbia University

Brief Summary:
The investigators will conduct a prospective, seven-month pilot study to explore pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the levonorgestrel intrauterine system (LNG IUS) for contraception. The investigators will enroll twenty women with well-controlled epilepsy maintained on stable anti-epileptic drugs (AED) therapy seeking the LNG IUS for contraception. The primary outcomes are AED levels and seizures before and after LNG IUS placement. Secondary outcomes include LNG levels, evidence of ovulation three weeks after insertion (serum progesterone >3ng/ml), bleeding and spotting, endometrial thickness, continuation, satisfaction and adverse events (removals, expulsions, side effects). The investigators will conduct a baseline month assessment, insertion visit, and follow-up visits at 21 days, three months and six months.

Condition or disease Intervention/treatment Phase
Epilepsy Contraception Drug: levonorgestrel IUS Phase 4

Detailed Description:

Study Procedures This pilot study consists of five study visits. Once preliminary eligibility is determined through a telephone screening interview, the first visit is scheduled.

Visit 1 Enrollment/Baseline

  • Review Eligibility
  • Informed Consent
  • Collect Baseline Information
  • Vital Signs
  • Pregnancy Test
  • Complete Physical Exam including Pelvic exam,
  • Chlamydia testing, and a Pap test if needed as per ASCCP (American Society for Colposcopy and Cervical Pathology) guidelines
  • Receive diary to record any bleeding or spotting
  • Receive condoms, if needed, for use until IUS insertion
  • Sign release for contact of primary neurologist or epileptologist
  • Study MD to contact participant's neurologist to notify of trial participation, and verify type and dose of AEDs

Visit 2 Insertion/4-6 Weeks from Baseline

  • Vital Signs
  • Pregnancy Test
  • Phlebotomy for hormone and AED levels
  • Transvaginal ultrasound
  • IUS Insertion
  • Review and collect completed diary
  • Receive new diary

Visit 3/ Follow up 3 Weeks post IUS Insertion

  • Vital Signs
  • Phlebotomy for hormone and AED levels
  • Transvaginal Ultrasound
  • Review and collect completed diary
  • Receive new diary

Visit 4/Follow up 3 Months post IUS Insertion

  • Vital Signs
  • Phlebotomy for hormone and AED levels
  • Transvaginal ultrasound
  • Review and collect completed diary
  • Receive new diary
  • Acceptability Questionnaire

Visit 5/ Exit 6 Months post IUS insertion

  • Vital Signs
  • Phlebotomy for hormone and AED levels
  • Transvaginal Ultrasound
  • Review and collect final completed diary
  • Acceptability Questionnaire

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
Study Start Date : August 2011
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
levonorgestrel IUS
all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
Drug: levonorgestrel IUS
placement of levonorgestrel intrauterine system
Other Name: Mirena




Primary Outcome Measures :
  1. Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level [ Time Frame: from baseline to 6 months after LNG IUS insertion ]
    The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of lamotrigine after IUD insertion.

  2. Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level [ Time Frame: from baseline to 6 months after LNG IUS insertion ]
    The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of levetiracetam after IUD insertion.

  3. Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level [ Time Frame: from baseline to 6 months after LNG IUS insertion ]
    The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of oxcarbazepine after IUD insertion.


Secondary Outcome Measures :
  1. Change in Seizure Frequency [ Time Frame: baseline to 6 months ]
    Number of participants with increased, unchanged or decreased mean monthly seizure frequency.

  2. Number of Participants Continuing With IUD [ Time Frame: 6 months ]
    Women continuing the IUD for contraception at 6 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age18-45 years
  2. Regular menstrual cycle of length 21-35 days
  3. Willing to use IUS for contraception
  4. Willing to use non-hormonal contraception for one month before insertion
  5. Stable AED therapy for at least two months
  6. Well-controlled epilepsy (2 or fewer seizures, other than simple partial, per month)
  7. Working telephone
  8. English Speaking

Exclusion Criteria:

  1. Current pregnancy or pregnancy in the previous two months
  2. Breastfeeding with amenorrhea
  3. Hepatic p450 enzyme inducing medications other than AEDs (griseofulvin, rifampin, St. John's Wort, bosentan)
  4. Depomedroxyprogesterone acetate within previous six months
  5. Congenital or acquired uterine anomaly, including myomas, that distort the uterine cavity
  6. Acute pelvic infection or a history pelvic infection without subsequent intrauterine pregnancy
  7. Postpartum endometritis or infected abortion in the last three months
  8. Genital bleeding of unknown etiology
  9. Untreated lower genital tract infection (cervical or vaginal)
  10. Acute liver disease or liver tumor, benign or malignant
  11. HIV infection or partner with HIV infection
  12. Increased susceptibility to pelvic infection
  13. A previously inserted intrauterine device (IUD) that has not been removed
  14. Hypersensitivity to any component of the LNG IUS
  15. Known or suspected carcinoma of the breast
  16. Current abnormal cervical cytology other than ASCUS or a history of abnormal cervical cytology other than ASCUS without appropriate follow-up demonstrating no evidence of disease
  17. History of genital tract malignancy
  18. Current use of anti-coagulants
  19. Current alcoholism or drug abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02362373


Locations
Layout table for location information
United States, New York
Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Anne Davis, MD Columbia University

Layout table for additonal information
Responsible Party: Anne Davis, Associate Professor of Clinical Obstetrics and Gynecology, Columbia University
ClinicalTrials.gov Identifier: NCT02362373     History of Changes
Other Study ID Numbers: AAAI0750
First Posted: February 12, 2015    Key Record Dates
Results First Posted: January 18, 2016
Last Update Posted: January 18, 2016
Last Verified: December 2015
Keywords provided by Anne Davis, Columbia University:
epilepsy
contraception
drug interaction
Additional relevant MeSH terms:
Layout table for MeSH terms
Levonorgestrel
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Anticonvulsants
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral